Key Insights

Highlights

Treatment Research

4 treatments under study, led by Cholesterol Absorption Inhibitor

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

100%

2 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Phase 4 (2)

Trial Status

Withdrawn1
Recruiting1

Clinical Trials (2)

Showing 2 of 2 trials
NCT06096909Phase 4Recruiting

Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population

NCT02941016Phase 4WithdrawnPrimary

Vascular Inflammation and Cholesterol Lowering Therapy

Showing all 2 trials

Research Network

Common Treatments

  • Cholesterol Absorption Inhibitor1
  • Statin1
  • Tafolecimab1
  • Evolocumab Or Alirocumab1

Active Sponsors

  • Innovent Biologics, Inc.1
  • China National Center for Cardiovascular Diseases1
  • Copenhagen University Hospital, Rigshospitalet1

Top Investigators

Related Conditions

  • Acute Coronary Syndrome1
  • Non St Segment Elevation Acute Coronary Syndrome1

Activity Timeline